دورية أكاديمية
Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis.
| العنوان: | Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis. |
|---|---|
| المؤلفون: | Alshahawey M; Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. nomar@fue.edu.eg., Ghazy M, El Morshedy M, El Said NO |
| المصدر: | European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2024 May; Vol. 28 (9), pp. 3365-3374. |
| نوع المنشور: | Journal Article; Comparative Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Verduci Country of Publication: Italy NLM ID: 9717360 Publication Model: Print Cited Medium: Internet ISSN: 2284-0729 (Electronic) Linking ISSN: 11283602 NLM ISO Abbreviation: Eur Rev Med Pharmacol Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Rome : Verduci, [1997- |
| مواضيع طبية MeSH: | Glucagon-Like Peptides*/economics , Glucagon-Like Peptides*/administration & dosage , Glucagon-Like Peptides*/therapeutic use , Liraglutide*/administration & dosage , Liraglutide*/economics , Liraglutide*/therapeutic use , Cost-Benefit Analysis* , Obesity*/drug therapy , Obesity*/economics , Overweight*/drug therapy , Overweight*/economics, Humans ; Injections, Subcutaneous ; Decision Support Techniques ; Weight Loss/drug effects ; Drug Administration Schedule ; Anti-Obesity Agents/economics ; Anti-Obesity Agents/administration & dosage ; Anti-Obesity Agents/therapeutic use ; Hypoglycemic Agents/economics ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/therapeutic use ; Cost-Effectiveness Analysis |
| مستخلص: | Objective: Obesity presents an enduring and multifaceted dilemma that impacts individuals, society, economies, and healthcare systems alike. Glucagon-like peptide-1 (GLP-1) receptor agonists, including liraglutide and semaglutide, have received FDA approval for obesity treatment. This study aims to present a cost-effectiveness analysis to compare the cost and clinical outcomes of semaglutide vs. liraglutide on weight loss in people with overweight and obesity. Materials and Methods: A cost-effectiveness analysis was conducted to compare the cost and the clinical outcomes of adding weekly 2.4 mg SC semaglutide vs. daily 3.0 mg SC liraglutide or placebo to physical activity and diet control in overweight and obese patients. A clinical outcome of achieving ≥15% weight loss was chosen. A simple decision analysis model from a third-payer perspective was applied. Drug costs were based on the retail price of the USA market. One-way sensitivity analyses were performed. Results: Results showed that 2.4 mg weekly semaglutide, when added to physical activity and diet control, was the most cost-effective choice in terms of ≥15% weight loss (ICER: $ 7,056/patient/68 weeks). The model was robust against the 50% increase in the unit cost of semaglutide and the 50% decrease in the unit cost of liraglutide, as well as the changes in probabilities by the corresponding 95% confidence intervals across the model. Conclusions: This cost-effectiveness analysis suggests that employing once-weekly 2.4 mg semaglutide emerges as a remarkably cost-effective option when contrasted with once-daily 3.0 mg liraglutide in patients with overweight and obesity when added to physical activity and diet control. |
| المشرفين على المادة: | 0 (semaglutide) |
| تواريخ الأحداث: | Date Created: 20240520 Date Completed: 20240520 Latest Revision: 20240520 |
| رمز التحديث: | 20240520 |
| DOI: | 10.26355/eurrev_202405_36181 |
| PMID: | 38766793 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2284-0729 |
|---|---|
| DOI: | 10.26355/eurrev_202405_36181 |